
    
      camrelizumab ， a humanized monoclonal antibody against PD-1, has been shown to block the
      binding of PD-1 to PD-L1, thereby inhibiting the immune escape of tumor cells. It has a high
      affinity for PD-1 (KD = 3.31 nmol/L), a high acceptor proportion (85% at 200 mg) of
      circulating T lymphocytes, and binds to epitopes different from Nivolumab and
      pembrolizumab，Phase 1 clinical trials have shown that camrelizumab is well tolerated and has
      antitumor activity in patients with advanced solid tumors.camrelizumab has been approved for
      indication for advanced hepatocellular carcinoma The main objective of this study was to
      observe and evaluate the safety and efficacy of treatment regiments containing carrelizumab
      in advanced liver cancer。 The subjects included people over 18 years old， For men and women
      with advanced liver cancer confirmed by histopathology or cytology;
    
  